3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
6
Phase 2
3
Phase NA
1
Status
Completed
2
Unknown
1
Sponsor Class
UNKNOWN
1
OTHER
1
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Conditions
Pain
3
Neoplasms
3
Marijuana Abuse
3
Recurrence
1
Parasomnias
1
Pancreatic Neoplasms
1
Nausea
1
Glioblastoma
1
Chronic Pain
1
Cachexia
1
Brain Neoplasms
1
Anxiety Disorders
1
Anorexia
1
Advanced Malignant Solid Tumor
1
Interventions
Morphine
6
Analgesia
6
nabiximols
3
Pregabalin
3
Oxycodone
3
Fentanyl
3
ziconotide
2
Surveys and Questionnaires
2
Saline Solution
2
Radiofrequency Ablation
2
Methadone
2
Lidocaine
2
Ketamine
2
Ibandronic Acid
2
Gemcitabine
2
Duloxetine Hydrochloride
2
Docetaxel
2
Botulinum Toxins, Type A
2
trimebutine 3-thiocarbamoylbenzenesulfonate
1
tanezumab
1
tandutinib
1
siltuximab
1
resiniferatoxin
1
incobotulinumtoxinA
1
imisopasem manganese
1
fulranumab
1
erenumab
1
cyclobenzaprine
1
caffeine, sodium benzoate drug combination
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Pain
×
nabiximols
×
Clear all
NCT03948074
2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2
Completed
91 enrolled
NCT03522467
2019-09-25
COPE
Aurora Cannabis Inc
Phase 2
Unknown
40 enrolled
NCT00530764
2013-06-20
SPRAY
GWPharm
Phase 2
Completed
360 enrolled
18 charts